On June 16, 2026, Médecins Sans Frontières (MSF) and other organizations urged EU lawmakers to reject plans to extend Supplementary Protection Certificates (SPCs) and to include access conditions for public funding in the forthcoming European Biotech Act. They argued that extending monopolies on medical products could hinder access to affordable treatments at a time when health systems are under financial strain. Discussions are ongoing among EU health ministers in Luxembourg, with recent committee opinions opposing the SPC extension. MSF emphasized that public investment should lead to improved public health outcomes, not increased barriers to access.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://msfaccess.org/public-investment-demands-public-benefits-european-biotech-act-must-deliver-people
